Nursing Management of Hypersensitivity and Infusion Reactions from Intravenously Administered Chemotherapeutic Agents
Keywords:
nursing role, hypersensitivity reactions, infusion reactionAbstract
Hypersensitivity and infusion reactions from intravenously administered chemotherapeutic agents are side effects resulting from the treatment of chemotherapy and monoclonal antibodies. Incidence, risk factors and severity depend on the types of medicine administered. Patients not being appropriately assessed or managed may result in life-threatening situations. Therefore, nurses who are in charge of administering chemotherapeutic drugs should have adequate knowledge and competencies to apply knowledge from evidence-based practice to improve effective care. This article mainly reviewed the definitions, mechanism, incidence, signs and symptoms, risk factors, prevention and management of hypersensitivity and infusion reactions from intravenously administered chemotherapeutic agents.
References
Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009;102:179-87.
Gobel BG. Chemotherapy-induced hypersensitivity reactions. Oncol Nurs Forum 2005;32:1027-35.
Vogel, WH. Infusion Reactions: Diagnosis, Assessment, and Management Clin J Oncol Nurs 2010; 14:10-21.
Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician 2003;68: 1781-90.
Ream M, Tunison D. Hypersensitivity reactions. In Yasko JM, Ed. Nursing management of symptoms associated with chemotherapy (5th), Bala Cynwyd, PA: Meniscus Limited; 2001.p.271-82.
Pagani M. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am 2010;94:835-52.
ชำนาญ เกียรติพีรกุล. Hypersensitivity Reactions Induced by Paclitaxel : Focus on Premedication การให้ยาป้องกันการเกิดภาวะภูมิไวเกิน (Hypersensitivity reactions) จากยา Paclitaxel. ศรีนครินทร์เวชสาร. 2548;20:99-104.
Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review. Met Based Drugs 2010; Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945654/. Accessed October 2017.
Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000;18:102-5.
Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol 2010;3:12.
Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 2013;68: 853-61.
Likmeta M, Shkoza A, Nina H. Case report a severe infusion reaction during the first dose of intravenously administered trastuzumab. ESJ 2015;11:1857-7881.
Price L, Brunt AM. Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose? Available at: http://ejhp.bmj.com/content/early/ 2017/ 04/17/ejhpharm-2016-001155. Accessed November 2017.
George TJ Jr, Laplant KD, Walden EO, Davis AB, Riggs CE, Close JL, et al. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. J Support Oncol 2010;8:72-7.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed September 2017.
Northern England Strategic Clinical Networks (NECN). Policy for the Management of Allergic Reactions and/or Hypersensitivity due to Chemotherapy and Monoclonal Antibodies 1.4.2015 Available at: www.necn.nhs.uk/.NECN-Allergic-Reactions-and-Hypersensitivity-Pol. Accessed September 2017.
Sendo T, Sakai N, Itoh Y, Ikesue H, Kobayashi H, Hirakawa T, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol 2005;56:91-6.
Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi H, et al. Risk factors for oxaliplatin induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 2011; 8:210-5.
Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, et al. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol 2014;15:1-6.
Mori Y, Nishimura T, Kitano T, Yoshimura K, Matsumoto S, Kanai M, et al. Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology 2010;79:136-43.
Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008;18:615-20.
Randall JM, Bharne AA, Bazhenova LA. Hypersensitivity reactions to carboplatin and cisplatin in nonsmall cell lung cancer. J Thorac Dis 2013;5:E53-7.
Schwartz JR, Bandera C, Bradley A, Brard L, Legare R, Granai CO, et al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants'Hospital. Gynecol Oncol 2007; 105:81-3.
Hopps S, Medina P, Pant S, Webb R, Moorman M, Borders E. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors. J Oncol Pharm Pract 2013;19:222-7.
O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, et al. High incidenceof cetuximabrelated infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007;25:3644-48.
Kang SP, Saif MW. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer-identification, prevention, and management. J Support Oncol 2007;5:451-7.
Boulanger J, Boursiquot JN, Cournoyer G, Lemieux J, Masse MS, Almanric K, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: CEPO review and clinical recommendations. Curr Oncol 2014;21:630-641.
Jung JW, Kang HR, Lee SH, Cho SH. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital. Oncology 2014;86:127-34.
Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, Runzer N, et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 2007;109:4171-73
อรอมล มาลีหวล, กชชุกร หว่างนุ่ม, เจษฎา มณีชวขจร, สุดสวาท เลาหวินิจ. ปัจจัยที่มีความสัมพันธ์กับการเกิดภาวะภูมิไวเกิน ในผู้ป่วยมะเร็งปอดที่ได้รับยาเคมีบำบัด Paclitaxel. วารสารกรมการแพทย์ 2559;41:105-17.
Patel J, Ho M, Ho V, Bello C, Djulbegovic B, Sokol L, et al. Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible? Leuk Res Treatment 2013; 2013:629283.
Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005;99: 393-9.
Jakel P, Carsten C, Carino A, Braskett M. Nursing Care of Patients Undergoing Chemotherapy Desensitization: Part II. Clin J Oncol Nurs 2016;20:137-9.
Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 2005;96:824-9.
Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, et al. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract 2016;4:497.
Viale PH. Management of hypersensitivity reactions: a nursing perspective. Oncology 2009;23:26-30.
สุพัตรา ฤกษ์วลีกุล. ภาวะภูมิคุ้มกันไวเกินจากยาเคมี บำบัดกลุ่มแพลทินัม. วารสารโรคมะเร็ง 2558;35:124-32
Wong JT, Ling M, Patil S, Banerji A, Long A. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract 2014;2:40-5.
Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.J Allergy Clin Immunol 2009;124:1259-66.
Canterbury District Health Board. Infusion related chemotherapy reactions. Available at: www.cdhb. health.nz/Hospitals-Services/Cancer-Blood-Services/Cytotoxic Biotherapy/ Documents/ Infusion%20Related%20Guidance2013.pdf. Accessed September 2017.
Joint Task Force on Practice Parameters: The diagnosis and management of anaphylaxis: an updated practice parameter. J Allerg Clin Immunol 2005;3:S438-S524.
Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574-80.
Gobel BH. Hypersensitivity Reactions to Biological Drugs. Semin Oncol Nurs 2007;2:191-200.
Downloads
Published
Issue
Section
License
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
